The Law Offices of Frank R. Cruz Continues Its Investigation of Loop Industries, Inc. (LOOP) on Behalf of Investors

The Law Offices of Frank R. Cruz continues its investigation of Loop Industries, Inc. (“Loop” or the “Company”) (NASDAQ: LOOP) on behalf of investors concerning the Company’s possible violations of federal securities laws.

If you are a shareholder who suffered a loss, click here to participate.

On October 13, 2020, Hindenburg Research published a report alleging, among other things, that “[a] former Loop employee told us that Loop’s scientists, under pressure from CEO Daniel Solomita, were tacitly encouraged to lie about the results of the company’s process internally. We have obtained internal documents and photographs to support their claims.” The report also stated that “Loop’s previous claims of breaking PET down to its base chemicals at a recovery rate of 100% were ‘technically and industrially impossible,’” according to a former employee. Moreover, the report alleged that “Executives from a division of key partner Thyssenkrupp, who Loop entered into a ‘global

Read More

The Law Offices of Frank R. Cruz Announces Investigation of Loop Industries, Inc. (LOOP) on Behalf of Investors

The Law Offices of Frank R. Cruz announces an investigation of Loop Industries, Inc. (“Loop” or the “Company”) (NASDAQ: LOOP) on behalf of investors concerning the Company’s possible violations of federal securities laws.

If you are a shareholder who suffered a loss, click here to participate.

On October 13, 2020, Hindenburg Research published a report alleging, among other things, that “[a] former Loop employee told us that Loop’s scientists, under pressure from CEO Daniel Solomita, were tacitly encouraged to lie about the results of the company’s process internally. We have obtained internal documents and photographs to support their claims.” The report also stated that “Loop’s previous claims of breaking PET down to its base chemicals at a recovery rate of 100% were ‘technically and industrially impossible,’” according to a former employee. Moreover, the report alleged that “Executives from a division of key partner Thyssenkrupp, who Loop entered into a ‘global

Read More

The Law Offices of Frank R. Cruz Announces Investigation of Homology Medicines, Inc. (FIXX) on Behalf of Investors

The Law Offices of Frank R. Cruz announces an investigation of Homology Medicines, Inc. (“Homology” or the “Company”) (NASDAQ: FIXX) on behalf of investors concerning the Company’s possible violations of federal securities laws.

If you are a shareholder who suffered a loss, click here to participate.

In June 2019, the Company launched a dose-escalation Phase 1/2 clinical trial for HMI-102, its lead product candidate for the treatment of phenylketonuria. Homology “reported encouraging safety and efficacy data from the dose-escalation portion of the trial” and claimed that the data showed HMI-102 “produced a sustained reduction in phenylalanine (Phe).”

Then, on July 21, 2020, Mariner Research published a report, alleging that the Company’s comments “conveniently ignor[ed] the implications to efficacy and the business.” Citing data from a mouse study, the Phase 1/2 trial, and a key patient’s Facebook posts, the report concluded that HMI-102 “therapy is showing zero efficacy even for a

Read More

The Law Offices of Frank R. Cruz Announces Investigation of Liberty Oilfield Services Inc. (LBRT) on Behalf of Investors

The Law Offices of Frank R. Cruz is investigating potential claims against the board of directors of Liberty Oilfield Services Inc. (“Liberty” or “the Company”) (NYSE: LBRT) concerning whether the board breached its fiduciary duties to shareholders.

If you are a shareholder, click here to participate.

On February 5, 2020, after the market closed, Liberty issued a press release announcing its financial and operations results for fourth quarter and full year 2019. Therein, Liberty reported full year adjusted EBITDA of $277 million, or a 37% decline over the prior year, and diluted earnings per share of $0.53, which fell significantly short of analyst forecasts.

On this news, Liberty’s stock price fell $1.07, or over 12%, to close at $7.80 per share on February 6, 2020, thereby injuring investors.

Our investigation concerns whether the Company’s board of directors breached its fiduciary duties to shareholders and/or grossly mismanaged the Company in connection

Read More

The Law Offices of Frank R. Cruz Announces Investigation of Amyris, Inc. (AMRS) on Behalf of Investors

The Law Offices of Frank R. Cruz is investigating potential claims against the board of directors of Amyris, Inc (“Amyris” or the “Company”) (NASDAQ: AMRS) concerning whether the board breached its fiduciary duties to shareholders.

If you are a shareholder, click here to participate.

On March 19, 2019, Amyris announced was unable to file its annual report for fiscal year ended December 31, 2018 on time due to “the significant time and resources that were devoted to the accounting for and disclosure of the significant transactions with Koninklijke DSM N.V. that closed in November 2018.” The Company also disclosed that it was “in the process of completing its evaluation of internal control over financial reporting.”

On this news, Amyris’ share price fell $0.78, or nearly 20% to close at $3.10 per share on March 20, 2019, thereby injuring investors.

Our investigation concerns whether the Company’s board of directors breached its

Read More

The Law Offices of Frank R. Cruz Announces Investigation of Aurora Cannabis, Inc. (ACB) on Behalf of Investors

Shareholders with losses exceeding $50,000 are encouraged to contact the firm

The Law Offices of Frank R. Cruz announces an investigation of Aurora Cannabis, Inc. (“Aurora” or the “Company”) (NYSE: ACB) on behalf of investors concerning the Company’s possible violations of federal securities laws.

If you are a shareholder who suffered a loss, click here to participate.

On September 8, 2020, the Company announced that it expected to record up to $1.8 billion in goodwill impairment charges in fourth quarter 2020. According to Aurora’s press release, these charges included “up to $90 million” in fixed asset impairment charges “due to production facility rationalization, and a charge of approximately $140 million in the carrying value of certain inventory, predominantly trim, in order to align inventory on hand with near term expectations for demand.”

On this news, the Company’s stock price fell $0.99 per share, or more than 11%, to close at

Read More

The Law Offices of Frank R. Cruz Continues Its Investigation of Mesoblast Limited (MESO) on Behalf of Investors

The Law Offices of Frank R. Cruz continues its investigation of Mesoblast Limited (“Mesoblast” or the “Company”) (NASDAQ: MESO) on behalf of investors concerning the Company’s possible violations of federal securities laws.

If you are a shareholder who suffered a loss, click here to participate.

On October 1, 2020, the Company disclosed that it had received a Complete Response Letter (“CRL”) from the U.S. Food and Drug Administration (“FDA”) regarding its marketing application for remestemcel-L for treatment of SR-aGVHD in pediatric patients. According to the CRL, the FDA recommended that Mesoblast “conduct at least one additional randomized, controlled study in adults and/or children to provide further evidence of the effectiveness of remestemcel-L for SR-aGVHD.” The CRL also “identified a need for further scientific rationale to demonstrate the relationship of potency measurements to the product’s biologic activity.”

On this news, Mesoblast’s stock fell $6.53, or 35%, to close at $12.03 per

Read More

The Law Offices of Frank R. Cruz Continues Its Investigation of Precigen, Inc. (PGEN) on Behalf of Investors

The Law Offices of Frank R. Cruz continues its investigation of Precigen, Inc. (“Precigen” or the “Company”) (NASDAQ: PGEN) on behalf of investors concerning the Company’s possible violations of federal securities laws.

If you are a shareholder who suffered a loss, click here to participate.

On September 25, 2020, the U.S. Securities and Exchange Commission (“SEC”) announced a $2.6 million civil penalty against the Company related to its statements about the “purported success converting relatively inexpensive natural gas into more expensive industrial chemicals using a proprietary methane bioconversion (‘MBC’) program.” In its cease-and-desist order, the SEC noted that “Intrexon was primarily using significantly more expensive pure methane for the relevant laboratory experiments but was indicating that the results had been achieved using natural gas.” Though the Company had pitched the program to business partners throughout 2017 and 2018, the SEC pointed out that a “number of the potential partners performed

Read More

The Law Offices of Frank R. Cruz Announces Investigation of Mesoblast Limited (MESO) on Behalf of Investors

The Law Offices of Frank R. Cruz announces an investigation of Mesoblast Limited (“Mesoblast” or the “Company”) (NASDAQ: MESO) on behalf of investors concerning the Company’s possible violations of federal securities laws.

If you are a shareholder who suffered a loss, click here to participate.

On October 1, 2020, the Company disclosed that it had received a Complete Response Letter (“CRL”) from the U.S. Food and Drug Administration (“FDA”) regarding its marketing application for remestemcel-L for treatment of SR-aGVHD in pediatric patients. According to the CRL, the FDA recommended that Mesoblast “conduct at least one additional randomized, controlled study in adults and/or children to provide further evidence of the effectiveness of remestemcel-L for SR-aGVHD.” The CRL also “identified a need for further scientific rationale to demonstrate the relationship of potency measurements to the product’s biologic activity.”

On this news, Mesoblast’s stock fell $6.53, or 35%, to close at $12.03 per

Read More

The Law Offices of Frank R. Cruz Announces Investigation of Precigen, Inc. (PGEN) on Behalf of Investors

The Law Offices of Frank R. Cruz announces an investigation of Precigen, Inc. (“Precigen” or the “Company”) (NASDAQ: PGEN) on behalf of investors concerning the Company’s possible violations of federal securities laws.

If you are a shareholder who suffered a loss, click here to participate.

On September 25, 2020, the U.S. Securities and Exchange Commission (“SEC”) announced a $2.6 million civil penalty against the Company related to its statements about the “purported success converting relatively inexpensive natural gas into more expensive industrial chemicals using a proprietary methane bioconversion (‘MBC’) program.” In its cease-and-desist order, the SEC noted that “Intrexon was primarily using significantly more expensive pure methane for the relevant laboratory experiments but was indicating that the results had been achieved using natural gas.” Though the Company had pitched the program to business partners throughout 2017 and 2018, the SEC pointed out that a “number of the potential partners performed

Read More